(Q30854780)

27 June 2017

Outcomes of persistently active neovascular age-related macular degeneration treated with VEGF inhibitors: observational study data (English)

1 reference

27 June 2017

1 reference

Rohan W Essex

9

0 references

Judy M Simpson

object named as

Judy M Simpson

4

0 references

Robyn H. Guymer

object named as

Robyn H Guymer

7

0 references

author name string

Daniel Barthelmes

1

1 reference

27 June 2017

Richard Walton

2

1 reference

27 June 2017

Anna E Campain

3

1 reference

27 June 2017

Jennifer J Arnold

5

1 reference

27 June 2017

Ian L McAllister

6

1 reference

27 June 2017

Alex P Hunyor

8

1 reference

27 June 2017

Nigel Morlet

10

1 reference

27 June 2017

Mark C Gillies

11

1 reference

27 June 2017

Fight Retinal Blindness! Project Investigators

12

1 reference

27 June 2017

language of work or name

English

0 references

publication date

23 September 2014

1 reference

British Journal of Ophthalmology

27 June 2017

1 reference

27 June 2017

99

1 reference

27 June 2017

359-364

1 reference

27 June 2017

3

1 reference

Ranibizumab versus verteporfin for neovascular age-related macular degeneration.

27 June 2017

1 reference

https://api.crossref.org/works/10.1136%2FBJOPHTHALMOL-2014-305514

Ranibizumab and bevacizumab for treatment of neovascular age-related macular degeneration: two-year results

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FBJOPHTHALMOL-2014-305514

Ranibizumab for neovascular age-related macular degeneration

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FBJOPHTHALMOL-2014-305514

A variable-dosing regimen with intravitreal ranibizumab for neovascular age-related macular degeneration: year 2 of the PrONTO Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FBJOPHTHALMOL-2014-305514

A treat and extend regimen using ranibizumab for neovascular age-related macular degeneration clinical and economic impact

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FBJOPHTHALMOL-2014-305514

Anti-VEGF Treatment Strategies for Wet AMD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FBJOPHTHALMOL-2014-305514

Long-term follow-up of central serous retinopathy in 150 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FBJOPHTHALMOL-2014-305514

Relocalization of apoptosis-inducing factor in photoreceptor apoptosis induced by retinal detachment in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FBJOPHTHALMOL-2014-305514

Ceramide production associated with retinal apoptosis after retinal detachment

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FBJOPHTHALMOL-2014-305514

Super-dose anti-VEGF (SAVE) trial: 2.0 mg intravitreal ranibizumab for recalcitrant neovascular macular degeneration-primary end point

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FBJOPHTHALMOL-2014-305514

SAVE (Super-dose anti-VEGF) trial: 2.0 mg ranibizumab for recalcitrant neovascular age-related macular degeneration: 1-year results

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FBJOPHTHALMOL-2014-305514

Efficient capture of high-quality data on outcomes of treatment for macular diseases: the fight retinal blindness! Project

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FBJOPHTHALMOL-2014-305514

Prospective audit of exudative age-related macular degeneration: 12-month outcomes in treatment-naive eyes

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FBJOPHTHALMOL-2014-305514

Baseline predictors for one-year visual outcomes with ranibizumab or bevacizumab for neovascular age-related macular degeneration

21 January 2018

1 reference

https://api.crossref.org/works/10.1136%2FBJOPHTHALMOL-2014-305514

10.1136/BJOPHTHALMOL-2014-305514

21 January 2018

Identifiers

DOI

1 reference

27 June 2017

1 reference